Eli Lilly should request approval for retatrutide early next year. This medicine could help the company expand the weight loss market.
Eli Lilly and Company delivered a monumental Q2 2026, with revenues up 48% to $23 billion, driven by MOUNJARO and ZEPBOUND. I maintain a 'Strong Buy' rating on the company, citing robust double-digit growth in key drugs and successful pipeline expansion, including positive phase 3 retatrutide data. EBGLYSS achieved 131% YoY sales growth and secured a label expansion, offering the only 6-dose annual maintenance regimen for moderate-to-severe AD.
The ETF market saw a massive surge into core index heavyweights this past week, as investors poured billions into broad U.S. equities and mega-cap tech leadership. However, this aggressive accumulation was paired with deliberate defensive positioning in ultra-short Treasuries, spot gold, and healthcare sector exposure.
CNBC's Jim Cramer said earnings season reinforced five investing themes he thinks will produce the market's best buying opportunities. He highlighted stocks to buy for each theme, including Capital One, Ralph Lauren, Lam Research, CrowdStrike, Goldman Sachs and Eli Lilly.
Eli Lilly's latest results made investors happy, as the stock jumped 5% on their release, as both revenues and earnings grew by strong double-digit percentages. While the company's blockbuster diabetes treatment Mounjaro led revenue growth, Zepbound gives some reasons for concern, along with other treatments. Strong margins and upgraded revenue guidance still significantly add to the stock, even as the EPS outlook was trimmed a bit.
Eli Lilly (NYSE:LLY | LLY Price Prediction) just delivered one of the cleanest beat-and-raise quarters I have seen from a mega-cap pharma in years.
Lilly lifts its 2026 outlook as Foundayo adoption accelerates, Medicare expands obesity access and retatrutide advances toward a 2027 filing.
Both Eli Lilly and Novo Nordisk beat second-quarter estimates and raised their full-year outlooks. But while investors cheered Lilly's results, they punished Novo a day earlier – underscoring a growing divide in Wall Street's confidence in the two obesity drug giants.
Eli Lilly remains a buy after Q2, with robust revenue growth and strong performance from Mounjaro and Zepbound. LLY raised 2026 revenue guidance to $85–87 billion, driven by volume gains despite price declines, and reinforced margin expansion. Retatrutide is a key medium-term catalyst, with a BLA submission planned for Q1 2027 and potential in new therapeutic areas.
As investors look to balance growth opportunities with defensive positioning, Acadia Pharmaceuticals, CVS Health, and Eli Lilly stand out as healthcare names combining resilient business models with strong earnings momentum.